Inhibition of PD-L1 palmitoylation with a general palmitoylation inhibitor 2-bromopalmitate (2-BP) or knock-down of DHHC3 decreases PD-1 binding and activates T cell cytotoxicity to promote antitumor immunity in the MC38 tumor model. This evidence concerns the gene CD274 and neoplasm.